Germany's Merck will provide update on new oncology acquisitions at ESMO 2017

31 August 2017

Germany’s Merck KGaA (MRK: DE) has said it will present 23 abstracts at next week’s European Society for Medical Oncology Congress (ESMO), one of the leading cancer conferences.

Data bolstering Erbitux (cetuximab) as a standard of care therapy will be presented, including quality of life data in colorectal cancer (CRC) and real-world data in both CRC and squamous cell carcinoma of the head and neck.

Merck says it will provide updated efficacy and safety data for avelumab in metastatic Merkel cell carcinoma and urothelial carcinoma among other cancers.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK